ProAssurance reports Q2 EPS 52c, consensus 21c

Reports Q2 revenue $276.8M, consensus $265.8M. The company said, “The quarter again illustrated benefits from our focus on ongoing actions to achieve sustained profitability, including price adequacy, disciplined underwriting and cost management, and we expect to see further progress in coming quarters. Joining forces with The Doctors Company through the transaction we announced in March will allow our organizations to continue to serve today’s healthcare providers with the necessary scale and breadth of capabilities. On June 24, ProAssurance (PRA) stockholders overwhelmingly approved the transaction, and on July 2 the Federal Trade Commission granted the transaction early termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976. The transaction remains subject to regulatory approvals by the insurance regulators in the domicile states (and District of Columbia) of ProAssurance’s insurance subsidiaries as well as other customary closing conditions, and is expected to close in the first half of 2026.”